Alluvi, previously BI 4744, represents a notable advance in obesity treatment. This dual agonist targeting both glucagon-like peptide-1 and GIP sites demonstrates compelling efficacy in patient trials, possibly https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/